^
Association details:
| Biomarker: | ROS1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
LBA28 - Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2 (ID 5510)
Published date:
09/28/2019
Excerpt:
From blood analysis, acquired resistance mutations were detected in 34% of NTRK+ solid tumour and 28% of the ROS1+ NSCLC cohorts, all of which were mutations in the kinase domain of the oncogenic driver.
Trial ID:
